The Asia Renal Denervation Consortium (ARDeC) consensus conference was convened to achieve consensus recommendations on renal denervation (RDN) and to help inform healthcare professionals in Asia.

**Consider RDN as a way to reduce blood pressure**
RDN could serve as a strategy for lowering blood pressure either alone or in combination with medication for Asian patients when blood pressure targets are difficult to achieve and maintain.

**Is proper procedural training in place?**
RDN should not necessarily be restricted to clinical trials or centers of excellence if proper procedural training is achieved.

**What is the patient’s cardiovascular risk profile?**
RDN should be considered for hypertensive patients with higher cardiovascular risk, including those with resistant uncontrolled hypertension and intolerance of or non-adherence to drug therapy.

**Is the patient taking antihypertensive medication?**
RDN should be considered in uncontrolled morning hypertension and residual nocturnal hypertension treated with antihypertensive medication.

**What is the patient’s preference?**
The decision to perform RDN should consider patient preference as part of a shared decision-making process between patient and physician.

---


UC202102316 ML ©2020 Medtronic. All rights reserved. Medtronic and the Medtronic logo are trademarks of Medtronic. All other brands are trademarks of a Medtronic company. For distribution only in markets where the Symplicity Spyral™ multi-electrode renal denervation catheter and Symplicity G3™ renal denervation RF generator have been approved. Not for distribution in the USA, Japan or France. 08/2020

Medtronic.com/RDN